Contains mecobalamin and 60 mg of UDCA
Enhanced B vitamins help relieve physical fatigue

Benfobell S, a high-dose active vitamin that combines mecobalamin, an ingredient used to treat peripheral neuropathy, with 60 mg of ursodeoxycholic acid (UDCA), an ingredient that improves liver function, for the first time in Korea, is drawing attention.


According to the pharmaceutical industry on October 26, Chong Kun Dang's Benfobell S is characterized by enhanced B vitamins compared with existing products and the addition of ingredients effective in relieving physical fatigue and improving liver function. In 2025, the Ministry of Food and Drug Safety revised the Standard for Manufacturing Medicinal Products, adding new ingredients for use in over-the-counter medicines and increasing the maximum daily dose.

Chong Kun Dang Benfobel S Tablet. Chong Kun Dang

Chong Kun Dang Benfobel S Tablet. Chong Kun Dang

View original image

The product contains an additional 500 mcg of mecobalamin, which regenerates damaged nerve cells and treats peripheral neuropathy and was previously prescribed as a prescription drug. Along with 100 mg of benfotiamine, an active form of vitamin B1, it also contains 30 mg of bisbentiamine, which crosses the blood-brain barrier and helps with energy metabolism in the brain.


The product contains 60 mg of ursodeoxycholic acid, the maximum amount permitted under the vitamin standard for manufacturing medicinal products. Known for stimulating bile secretion and protecting liver cells, the ingredient is combined with taurine, methionine, and orotic acid to help restore physical energy depleted by impaired liver function.



A Chong Kun Dang representative said, "Benfobell S is a product that provides, in one tablet a day, B vitamins—which modern people can easily become deficient in due to stress, drinking, smoking, and nutritional imbalances—as well as ingredients that help strengthen liver function."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing